Temsirolimus for metastatic renal cell carcinoma (stage IV) - horizon scanning review
NHSC
Record ID 32005000228
English
Authors' objectives:
This study aims to assess the effectiveness of temsirolimus for metastatic renal cell carcinoma (stage IV).
Authors' recommendations:
Temsirolimus (CCI-779) inhibits the protein mTOR kinase and prevents cell division and hence tumour growth. It is currently in phase III clinical trials for the first-line treatment of advanced or metastatic renal cell carcinoma (RCC) with poor prognosis. The study is evaluating temsirolimus monotherapy and combination therapy with interferon-alpha (IFN-), versus IFN- alone in 600 patients. Results from a phase II study in 111 patients showed an objective response rate of 7% (one complete response and seven partial responses). Median time to tumour progression was found to be 5.8 months and median survival was 15.0 months.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Neoplasm Metastasis
- Carcinoma, Renal Cell
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.